logo
Plus   Neg
Share
Email

Stock Alert: AC Immune Tanks 40% As Alzheimer's Drug Fails To Meet Primary Endpoint

Shares of AC Immune SA (ACIU) are losing over 40% on Wednesday morning after its mid-stage study evaluating Semorinemab in early alzheimer's disease failed to meet primary goals.

ACIU is currently trading at $4.96, down $3.76 or 43.12%, on the Nasdaq.

AC Immune said its partner Genentech, a member of the Roche Group, has informed top line results from a Phase 2 trial of the anti-Tau antibody, semorinemab, in early Alzheimer's disease which show that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes compared to placebo.

Two secondary endpoints, Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 and Alzheimer's Disease Cooperative Study Group - Activities of Daily Living Inventory were also not met.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Eli Lilly and Co. (LLY) will end a phase III clinical trial for its COVID-19 antibody treatment in the U.S., due to insufficient evidence on improved clinical outcomes. Orca Bay Foods, LLC recalled about 4,450 pounds of Trader Joe's brand Gluten Free Battered Halibut products for undeclared wheat and milk allergens, according to a statement published by the U.S. Food and Drug Administration (FDA). The action was initiated after it was discovered that product containing Wheat and Milk was distributed in packaging. Lee Kun-hee, the Chairman of South Korean conglomerate Samsung Group, has died on October 25, at the age of 78. It was he who transformed Samsung into a South Korean behemoth, and the world's largest manufacturer of smartphones, televisions, and semiconductors. As per reports, Lee's only son Jae-yong, who currently serves as vice chairman of Samsung Electronics, is likely to take over Samsung.
RELATED NEWS
Follow RTT